Sangamo Therapeutics (SGMO) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 6119.28%.
- Sangamo Therapeutics' EBIT Margin fell 61407900.0% to 6119.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 342.59%, marking a year-over-year decrease of 747900.0%. This contributed to the annual value of 179.88% for FY2024, which is 244000.0% down from last year.
- Latest data reveals that Sangamo Therapeutics reported EBIT Margin of 6119.28% as of Q3 2025, which was down 61407900.0% from 97.54% recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' EBIT Margin registered a high of 21.52% during Q3 2024, and its lowest value of 10712.27% during Q1 2024.
- Moreover, its 5-year median value for EBIT Margin was 205.44% (2022), whereas its average is 1966.66%.
- In the last 5 years, Sangamo Therapeutics' EBIT Margin crashed by -107236800bps in 2024 and then surged by 103193200bps in 2025.
- Sangamo Therapeutics' EBIT Margin (Quarter) stood at 169.58% in 2021, then dropped by -20bps to 203.42% in 2022, then tumbled by -1394bps to 3039.13% in 2023, then surged by 87bps to 399.85% in 2024, then tumbled by -1430bps to 6119.28% in 2025.
- Its last three reported values are 6119.28% in Q3 2025, 97.54% for Q2 2025, and 460.28% during Q1 2025.